NEW YORK, June 25, 2019 /PRNewswire/ -- Oppenheimer
& Co. Inc. ("Oppenheimer") – a leading investment bank, wealth
manager, and a subsidiary of Oppenheimer Holdings (NYSE: OPY) –
will host its Montauk Emerging Life Sciences Summit at Gurney's
Star Island Resort in Montauk, NY
from June 26-28, 2019. This event
will feature informed and insightful commentary on emerging
treatments and the latest advancements in Biotechnology and Life
Science companies across panels and 1-on-1 meetings with
attendees.
The gathering will showcase a diverse mix of companies
representing insight and focus across a range of research areas.
Companies participating include: Alpine Immune Sciences, Caribou
Biosciences, IMV, Kadmon, Milestone Pharmaceuticals, Molecular
Templates, Pear Therapeutics, and Tvardi Therapeutics.
The event will feature four panel discussions, moderated by
Oppenheimer Life Science Research Analysts, addressing key current
issues in oncology and healthcare as follows:
- IPO/APO Financing Opportunities for Emerging Companies
with Megan Gates, Mintz, Levin Cohn,
Ferris, Glovsky and Popeo, P.C., Mitch
Gold, Chairman & CEO of Alpine Immune Sciences,
Michael Rice, Co-Founder of LifeSci
Advisors, Dietrich Stephan, CEO,
Neubase Therapeutics, Ben Taylor,
President & CFO of Tyme, moderated by Michael Margolis and Stefan Loren
- Advances in Cancer Cell Therapies with Dr. Renier Brentjens, M.D., Ph.D., Scientific
Co-Founder of Juno Therapeutics Inc., moderated by Mark Breidenbach
- Financing and Investing in Emerging Biotech with
Robert Connelly, CEO of Elicio
Therapeutics, Ross Leimberg,
Director at AbbVie Ventures, Dennis
Patrick, Ph.D., VP, WRD, Pfizer, Rohit Vanjani, Senior Associate at General
Atlantic, moderated by Jay
Olson
- Promises & Challenges of Gene Editing in the Age of
CRISPR with Dr. Neville Sanjana,
Core Faculty Member at the NY Genome Center and Assistant Professor
in the Departments of Biology and of Neuroscience and Physiology at
NYU, moderated by Silvan Tuerkcan
Oppenheimer Senior Research Analysts will also be in attendance
to offer additional insights:
- Mark Breidenbach, Ph.D.,
Executive Director and Senior Analyst covering Biotechnology
- Kevin DeGeeter, Managing
Director and Senior Analyst covering Biotechnology
- Leland Gershell, Managing
Director and Senior Analyst covering Biotechnology
- Jay Olson, Managing Director and
Senior Analyst covering Biopharmaceuticals
- Esther Rajavelu, Executive
Director and Senior Analyst covering Biotech and Specialty
Pharmaceuticals
- Hartaj Singh, Managing Director and Senior
Analyst covering Biotechnology
- Silvan Tuerkcan, Ph.D., Director covering Biotechnology
"As a leader in life science equity research, we are proud to
offer our clients access to prominent scientists and companies,
providing them with insights into innovative technologies and
state-of-the-art therapies and showcasing the significant
investment opportunities presented by these organizations," said
Michael Margolis, Managing Director
and Co-Head of Healthcare Investment Banking.
Oppenheimer's next conference is the 22nd Annual
Technology, Internet, and Communications Conference, which will be
held on August 6-7, 2019 in
Boston, MA. Midwest Corporate
Access Day will follow on August 15
in Chicago, IL.
Oppenheimer & Co. Inc.
Oppenheimer &
Co. Inc. (Oppenheimer), a principal subsidiary of Oppenheimer
Holdings Inc. (OPY on the New York Stock Exchange), and its
affiliates provide a full range of wealth management, securities
brokerage and investment banking services to high-net-worth
individuals, families, corporate executives, local governments,
businesses and institutions.
View original
content:http://www.prnewswire.com/news-releases/oppenheimer-gathers-life-science-leaders-and-investors-for-montauk-emerging-life-sciences-summit-300874129.html
SOURCE Oppenheimer & Co. Inc.